Patient Community Events

GIST patient community update on BLU-285 clinical program

Dr. Anthony Boral, chief medical officer of Blueprint Medicines, will provide an update on the clinical development of BLU-285, an investigational medicine being developed for patients with advanced GIST. The presentation will include an update on results from Blueprint Medicines’ ongoing Phase 1 clinical trial of BLU-285 in patients with advanced GIST presented at the American Society of Clinical Oncology conference in Chicago, IL on Monday June 5th.

Date and Time: Thursday, June 22nd from 12-1 pm (EST)
The following is a recording of this webinar:

gist20170622